Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Research & Development (2016 - 2025)

Ocular Therapeutix has reported Research & Development over the past 13 years, most recently at $50.8 million for Q4 2025.

  • Quarterly results put Research & Development at $50.8 million for Q4 2025, up 23.94% from a year ago — trailing twelve months through Dec 2025 was $197.1 million (up 54.42% YoY), and the annual figure for FY2025 was $197.1 million, up 54.42%.
  • Research & Development for Q4 2025 was $50.8 million at Ocular Therapeutix, down from $52.4 million in the prior quarter.
  • Over the last five years, Research & Development for OCUL hit a ceiling of $52.4 million in Q3 2025 and a floor of $10.9 million in Q1 2021.
  • Median Research & Development over the past 5 years was $15.1 million (2023), compared with a mean of $24.5 million.
  • Biggest five-year swings in Research & Development: dropped 5.48% in 2022 and later soared 153.1% in 2024.
  • Ocular Therapeutix's Research & Development stood at $12.6 million in 2021, then grew by 7.67% to $13.5 million in 2022, then increased by 19.58% to $16.2 million in 2023, then soared by 153.1% to $41.0 million in 2024, then rose by 23.94% to $50.8 million in 2025.
  • The last three reported values for Research & Development were $50.8 million (Q4 2025), $52.4 million (Q3 2025), and $51.1 million (Q2 2025) per Business Quant data.